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  We previously induced protective immune response by 
oral  immunization  with  yeast  expressing  the  ApxIIA 
antigen. The ApxI antigen is also an important factor in 
the protection against Actinobacillus pleuropneumoniae se-
rotype 5 infection; therefore, the protective immunity in 
mice following oral immunization with Saccharomyces cer-
evisiae  expressing  either  ApxIA  (group  C)  or  ApxIIA 
(group D) alone or both (group E) was compared with that 
in  two  control  groups  (group  A  and  B).  The  immuno-
genicity of the rApxIA antigen derived from the yeast was 
confirmed by a high survival rate and an ApxIA-specific 
IgG  antibody  response  (p ＜0.01).  The  highest  systemic 
(IgG)  and  local  (IgA)  humoral  immune  responses  to 
ApxIA  and  ApxIIA  were  detected  in  group  E  after  the 
third immunization (p ＜ 0.05). The levels of IL-1β  and 
IL-6 after challenge with an A. pleuropneumoniae field iso-
late did not change significantly in the vaccinated groups. 
The level of TNF-α increased in a time-dependent manner 
i n  g r o u p  E  b u t  w a s  n o t  s i g n i f i c a n t l y  d i f f e r e n t  a f t e r  t h e  
challenge. After the challenge, the mice in group E had a 
significantly lower infectious burden and a higher level of 
protection than the mice in the other groups (p ＜0.05). 
The survival rate in each group was closely correlated to 
the immune response and histopathological observations 
in the lung following the challenge. These results suggested 
that immunity to the ApxIA antigen is required for opti-
mal protection. 
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Introduction 
  Most pathogens infect their host across mucosal surfaces, 
particularly those of the gastrointestinal tract or respiratory 
tract [24]. Immunoglobulin A (IgA) is the most abundant 
Ig isotype present in the mucosal tissue during infection 
and is crucial as a first line of defense. The main role of se-
cretory IgA in oral immunization [8,22] is to protect the 
host by inhibiting pathogen attachment, immune ex-
clusion, and facilitating the clearance of toxic products 
[37]. IgA may also function in lung defense by influencing 
the trafficking of specific cells through the common mu-
cosal immune system [19]. The important roles that both 
specific local IgA and systemic IgG play in the protection 
from respiratory diseases have been well documented 
[11,12]. Although most bacterial extracts that are com-
monly administered orally produce nonspecific or poor 
immune responses, we previously demonstrated that the 
protection against Actinobacillus pleuropneumoniae in-
creased with the production of specific IgA in the lung 
[34]. In addition, the induction of protective immunity in 
A. pleuropneumoniae infection by eliciting specific IgA 
and IgG after natural and experimental infection has been 
investigated [18].
  A. pleuropneumoniae is the etiological agent of porcine 
pleuropneumonia, a severe respiratory disease affecting 
swine, is characterized by necrotizing fibrinous pneumo-
nia and pleuritis [6]. Although the bacterium produces sev-
eral virulence factors, the virulence of A. pleuropneu-
moniae is strongly correlated with the production of Apx 
exotoxins. Four different types of exotoxins, ApxI, ApxII, 
ApxIII and ApxIV, have been characterized in this bacte-
rium [15,28]. Both ApxIA and ApxIIA of A. pleuro-
pneumoniae are essential for full virulence in the develop-384    Sung Jae Shin et al.
ment of clinical signs and typical lung lesions [5,28]. No 
preventive strategies have shown complete protection 
against the disease to date. Vaccination is thought to be the 
most effective way to prevent clinical signs by infection 
with the bacterium and many studies have focused on the 
development of novel vaccines to prevent A. pleuro-
pneumoniae infection [5,17,18,26,32,39]. However, most 
vaccines have taken the form of injections, which are labo-
rious and time-consuming, cause discomfort to the animal, 
and may cause adverse effects, such as the induction of an 
inflammatory response at the injection site [16,18,26]. 
  Saccharomyces cerevisiae, commonly known as baker's 
yeast, has recently been adopted as a delivery vehicle for 
oral immunization [3]. This organism can express large 
quantities of heterogenous proteins at a relatively low cost 
[1,30] and is considered to be safe for human consumption 
[31]. In addition, S. cerevisiae has been used as a tracer for 
the oral application of vaccines and drugs because it is rela-
tively stable, nonpathogenic, and noninvasive in the gut in 
comparison to other biodegradable vehicles [2,30]. The 
yeast may also stimulate the host mucosal immune system 
by interacting with intestinal epithelial cells in the presence 
of butyric acid, a metabolite produced by intestinal bac-
teria [29]. 
  In addition to the induction of a specific antibody re-
sponse, delivery systems and adjuvants are also key factors 
in designing an oral vaccine to efficiently induce a mucosal 
immune response [19,20,22]. Although several systems 
have been developed, they have failed to induce sufficient 
immune responses due to antigen dilution or denaturation, 
tight immune regulation at mucosal sites, toxicity, or in-
sufficient immunostimulatory effects [27,40]. The recent 
success using S. cerevisiae as a delivery vehicle in oral im-
munization [3,4,29,38] led us to choose this yeast system 
for the delivery vehicle in our study.
  Based on current knowledge, we propose that S. cer-
evisiae expressing Apx toxins is a more effective way to in-
duce protective immunity against A. pleuropneumoniae in-
fection than single administration of the ApxIIA. We first 
confirmed the immunogenicity of the yeast-derived 
ApxIA antigen. We then investigated the local and sys-
temic immune responses, bacterial clearance, and in-
flammatory responses after oral immunization and 
challenge. Finally, we evaluated the protective efficacy of 
our vaccine strategy by challenge with a field isolate of A. 
pleuropneumoniae serotype 5. 
Materials and Methods
Preparation of vaccines
  The apxIA and apxIIA genes were cloned from A. pleuro-
pneumoniae serotype 5 isolated from the lungs of Korean 
pigs with pleuropneumonia. For the oral vaccine, S. cer-
evisiae expressing ApxIA or ApxIIA antigens were pre-
pared as previously described [34,35]. 
Experimental animals
  Female  5-week-old  BALB/c mice (Breeding and Re-
search Center, Seoul National University, Korea) were 
used throughout this study in accordance with the policies 
and regulations for the care and use of laboratory animals 
(Seoul National University, Korea). All animals were pro-
vided with standard mouse chow and water ad libitum. 
  The immunogenicity of the ApxIA produced in the yeast 
was confirmed by subcutaneous immunization with 
yeast-derived ApxIA protein, and the survival rate after 
challenging with a clinical strain of A. pleuropneumoniae 
was determined as previously described [34]. 
  Briefly, 15 mice per group were subcutaneously injected 
with 100 µg of protein extract after emulsifying with com-
plete Freund's adjuvant (Sigma, USA). This was then fol-
lowed by a boost immunization with the same amount of 
antigens after emulsifying with incomplete Freund's ad-
juvant (Sigma, USA) at 2 weeks after the initial immu-
nization. The final immunization was performed in the 
same manner at 2 weeks after the boost immunization. 
Blood was drawn to collect serum at 5 days after the final 
boost immunization. Finally, a survival test and IgG anti-
body response assays were carried out in order to confirm 
the immunogenicity of the yeast-derived ApxIA antigen.
Each experimental group in the oral vaccination study con-
sisted of 40 mice, and each was allocated to one of five im-
munization regimens. Group A (control) received oral ad-
ministration of 500 µl of 10 mM PBS (pH 7.2) and group 
B (vector) was orally vaccinated with 20 mg of S. cer-
evisiae powder dissolved into 500 µl of 10 mM PBS (pH 
7.2). The vaccinated groups were immunized with 20 mg 
of  S. cerevisiae expressing either ApxIA (group C), 
ApxIIA (group D), or both (10 mg each, group E) dissolved 
with the procedures as well.  
Delivery of vaccines for immunization and collec-
tion of samples
  All groups were immunized orally through an oral gavage 
with 4 doses at 10-day intervals. Five mice from each im-
munization group were randomly selected after 2 days 
(Fig. 1). Samples of lung, intestine, and serum were in-
dividually collected from the mice as described previously 
[34]. All serum samples were stored at 򰠏20
oC until use. 
Half of the lung and small intestine samples were homo-
genized with 10,000 RPM homogenization (Polytron 
PT3000; Kinematica, USA). The homogenized samples 
were stored at 4
oC overnight, then centrifuged at 12,000 × 
g for 10 min at 4
oC. The supernatants were collected for 
subsequent analysis and stored at 򰠏20
oC until use. The total 
protein concentration in each sample was measured using 
the BCA protein assay kit (Pierce, USA) and normalized to 
1 mg immediately before performing the assay.Immune responses with S. cerevisiae expressing rApxIA or rApxIIA    385
                             Fig. 1. Schematic of protocols for oral vaccine delivery.
Immune response analysis
  Antibody titers (IgA and IgG) against ApxIA or ApxIIA 
of A. pleuropneumoniae were measured by ELISA in order 
to analyze the immune response in the mice. For this assay, 
100 µg of rApxIA and rApxIIA [33] resuspended in 100 µl 
of coating buffer (14.2 mM Na2CO3, 34.9 mM NaHCO3, 
3.1 mM NaN3, pH 9.6) was added to a microplate for 
ELISA (Greiner, Australia) and incubated overnight at 
4
oC. The plate was washed three times with PBST (0.05% 
Tween 20 in PBS) and blocked with PBST containing 1% 
bovine serum albumin by incubation for 1 h at 37
oC. After 
incubation with primary antigens, sera from the immu-
nized mice, lung or intestinal homogenates, were added to 
the plate and incubated for 1 h at 37
oC. After washing three 
times with PBST, 100 µl of goat anti-mouse IgG (H + L)- 
HRP conjugate (Bio-Rad, USA) or anti-mouse IgA (α
-chain specific)-HRP conjugate (Sigma, USA) was added 
to the plate and incubated for 1 h at 37
oC. Color was devel-
oped by adding 100 µl of ABTS substrate solution (Bio- 
Rad, USA) to the plate. After incubation for 20 min at room 
temperature, the O.D. was measured at 405 nm using an 
ELISA reader (Molecular Device, USA).
Immunohistochemistry
  Immunohistochemical staining was followed by our pre-
vious report [34]. 
  Tissue  preparation: For tissue preparation, mice from 
each group were deeply anesthetized with a mixture of xy-
lazine hydrochloride (Bayer, Korea) and ketamin hydro-
chloride (Yuhan, Korea) and then perfused intracardially 
with 0.9% saline, followed by a fixative (4% parafor-
maldehyde in 0.1 M PBS, pH 7.4) at a rate of 70 ml/min 
with a perfusion pump (Masterflex, USA). After perfusion, 
the lungs and intestines were removed and post-fixed over-
night in the same fixative at 4
oC. The lungs and intestines 
were cryoprotected by transfer to 30% sucrose in 0.1 M 
PBS and frozen in OCT embedding medium (Tissue-Tek; 
Sakura, USA) for storage at 򰠏70
oC. Tissues were cut into 
12 µm thick coronal sections with a cryostat (Reichert- 
Jung, Germany), mounted on silane-coated slides (DAKO, 
Denmark) and stored at 򰠏70
oC until processing for immu-
nohistochemistry.
  Detection of Apx toxin-specific antibody-producing 
cells: Tissue sections were rinsed with 0.01 M PBS (pH 
7.4) and treated with 0.5% hydrogen peroxide in 0.01 M 
PBS for 15 min. The sections were washed three times for 
10 min each with 0.01 M PBS, then blocked by incubation 
in 10% normal goat serum (DAKO, Denmark) or 10% 
skim milk in 0.1 M PBS for 1 h at room temperature. The 
sections were incubated with 50 µg/ml of rApxIA or 
rApxIIA in 0.1 M PBS overnight at 4
oC. After incubation 
with primary antigens, the sections were washed three 
times with 0.01 M PBS for 10 min each and then incubated 
with 1 : 200 diluted polyclonal antibodies against a culture 
supernatant of A. pleuropneumoniae serotype 2 and 5 in 0.1 
M PBS containing 0.3% triton X-100 and 2% normal goat 
serum for 2 h at room temperature. After washing with 0.01 
M PBS for 10 min, the sections were sequentially reacted 
with 1 : 200 diluted goat anti-rabbit IgG (Vector, USA) and 
Streptavidin (Vector, USA) in the same solution. Between 386    Sung Jae Shin et al.
sequential reactions, the tissues were washed three times 
with PBS for 10 min each. The sections were visualized 
with 3'3-diaminobenzidine tetrachloride (Sigma, USA) in 
0.1 M Tris buffer (pH 6.8) and mounted with a cover slide 
after counterstain with hematoxylin. Immunoreactive pre-
cipitates were observed under an Axioplan microscope 
(Carl Zeiss, Germany). Images of IgA immunoreactivity in 
ten villi in the small intestine and 10 alveolar spaces in the 
lung were randomly chosen from each animal and captured 
with an AppleScanner (Apple Computer, USA). The 
brightness and contrast of each image file were uniformly 
calibrated by Adobe Photoshop version 2.4.1, followed by 
analysis using NIH Image 1.59 software. Background 
staining values were subtracted from the immunoreaction 
intensities. The number of IgA-secreting cells in alveolar 
spaces was counted using Optimas 6.5 software (Media-
Cybernetics, USA) by averaging the counts from 10 sec-
tions randomly taken from the same section level of each 
group. 
Bacterial challenge and survival rate
  Mice in each group were challenged by intraperitoneal in-
jection of a field isolate of A. pleuropneumoniae serotype 
5 at 1.45 × 10
6 CFU (minimal lethal dose, MLD) in 10 days 
after their final immunization, and were then monitored 
every 6 h for up to 72 h. During the monitoring, animals 
that succumbed to the challenge were dissected and lung 
tissues were collected for subsequent analysis of in-
flammatory responses, cytokines, and recovery. 
Bacteriological examination
  To assess the protective efficacy measured by bacterial 
clearance in the lungs, lungs were aseptically removed at 
72 h post-challenge. The lungs were homogenized in 5 ml 
of PBS using a tissue homogenizer. Each homogenate was 
serially diluted in PBS and 50 µl of the homogenate, and 
the diluted samples (in triplicate) were then plated on choc-
olate agar plates. The plates were incubated at 37
oC for 48 
h under a 5% (V/V) CO2 atmosphere. The number of live 
bacteria was quantified according to the formula: CFU/ml 
= mean no. of colonies × dilution factor × 20. Differences 
were considered to be significant if a probability value of p 
＜ 0.05 was obtained when the CFU count of the immu-
nized groups was compared to that of the control groups.  
Histological examination
  The mice were sacrificed at 72 h after challenge with the 
MLD of A. pleuropneumoniae serotype 5, and the lungs 
were sliced into pieces and preserved in 10% neutralized 
buffer formalin. The tissue samples were embedded in par-
affin, cut into 6 µm sections, assessed by routine staining 
with hematoxylin and eosin, and examined by light 
microscopy. The inflammatory response was evaluated by 
examining the lung tissue for the presence of typical in-
flammatory signs [36]. Inflammatory index was obtained 
from the average of the score from each inflammatory re-
sponse in 5 fields of each mouse. The severity of the in-
flammatory response (congestion, neutrophil infiltration, 
exudation, consolidation, infiltration of fibrosis and plate-
lets) was ranked using a score of 0 to 3 for each symptom 
(0, no sign; 1, mild; 2, notable and local; 3, severe and 
spread) based on the size and number of lesions per field.
Cytokine analysis
  The levels of TNF-α, IL-1β, and IL-6 in the serum and 
lungs were quantified by ELISA (Endogen, USA) accord-
ing to the instructions supplied by the manufacturer. Lung 
samples and sera from all experimental groups were pre-
pared as described previously [9]. Briefly, aseptically pre-
pared lungs were homogenized in 3 ml of lysis buffer. Lung 
homogenates were incubated on ice for 30 min and then 
centrifuged at 2,500 rpm for 10 min. The supernatants were 
collected and filtered using 0.45 µm syringe filters (Nalgen, 
USA). Before conducting the cytokine assessments, the 
protein concentration of each homogenate was normalized 
to 1 mg using a BCA protein assay kit (Pierce, USA). The 
amount of each cytokine was calculated by comparison 
with a standard curve generated by serial dilutions of mur-
ine recombinant cytokines.  
Statistical analysis
  Changes in IgA-secreting cells according to immuniza-
tion time and treatment group were evaluated with 
ANOVA. The antibody titer and cytokine quantification 
results were expressed as the mean ± SD. Differences be-
tween control groups and vaccinated groups were analyzed 
by a two-tailed independent Student's t-test. Differences 
were considered to be significant if probability values of p 
＜ 0.05 were obtained.
Results
Immunogenicity of yeast expressing ApxIA antigen
  To initially confirm the immunogenicity of the yeast-de-
rived ApxIA antigen, the production of ApxIA-specific 
IgG antibodies and survival rates were investigated as in 
our previous study of the yeast-derived ApxIIA antigen 
[34]. The levels of ApxIA-specific IgG antibody were sig-
nificantly increased by subcutaneous immunization with 
the protein extracted from the yeast expressing ApxIA. 
Mice challenged with the MLD of an A. pleuropneumoniae 
field isolate had a higher survival rate (70%) than the con-
trol (0%). None of the mice in the control groups showed 
significant production of specific antibody or protection 
against A. pleuropneumoniae after the challenge (data not 
shown). Immune responses with S. cerevisiae expressing rApxIA or rApxIIA    387
Fig. 2. Specific-IgA antibody responses to Actinobacillus pleu-
ropneumoniea AxpIIA or ApxIA toxin in the lung (A), small in-
testine (B), and sera (C) of mice orally immunized with S. cer-
evisiae (□, group A; ■, group B; 򰌔򰌔, group C; ▧, group D; ▤,
group E). Bars represent the mean O.D. values at 405 nm. Error
bars represent the standard deviation from the mean. Significant 
differences between control groups and vaccinated groups are 
expressed as *p ＜ 0.05 and ** p ＜0.01.
Fig. 3. Systemic specific IgG (A) and specific-IgM antibody re-
sponses (B) against Actinobacillus pleuropneumoniea AxpIIA or
ApxIA toxin in the sera of mice orally immunized with S. cer-
evisiae (□, group A; ■, group B; 򰌔򰌔, group C; ▧, group D; ▤,
group E). Bars represent the mean O.D. values at 405 nm. Error
bars represent the standard deviation from the mean. Significant 
differences between the control and vaccinated groups are ex-
pressed as *p ＜ 0.05 and **p ＜ 0.01.
Induction of specific immune responses
  The levels of local and systemic antibodies specific to the 
Apx antigens were investigated in mice orally immunized 
with Apx antigen-expressing yeast. The antibodies specif-
ic to ApxIA or ApxIIA were produced at similar levels in 
the group immunized with both the ApxIA and ApxIIA 
antigens. Mucosal immune responses were evaluated in 
the lung (Fig. 2A), intestine (Fig. 2B) and sera (Fig. 2C). 
Specific IgA responses to ApxIA or ApxIIA in the intes-
tines and lungs from mice immunized with yeast express-
ing Apx antigens were significantly higher than those in 
the control groups after the second and third immuniza-
tions, respectively (p ＜ 0.05). In particular, mice immu-
nized with a single antigen (either ApxIA or ApxIIA) 
showed significant increases in the level of specific IgA at 
the final immunization (day 40) in both the lung and intes-
tine (p ＜ 0.05). However, no significant increases in spe-
cific IgA antibodies were observed in the sera of any ex-
perimental group, even though the levels of specific IgA 
were slightly higher in the vaccinated groups (p ＜ 0.05) 
(Fig. 2C). 
  Systemically, the pattern of IgG production to ApxA anti-
gens in the sera was similar to that of IgA. Increases in IgG 
antibodies were only observed in the group immunized 
with both antigens after the 2nd immunization and were 
maintained until the final immunization, while groups vac-
cinated with a single antigen showed no significant differ-
ence during the same period (p  ＞  0.05) (Fig. 3A). 
Interestingly, similar levels of IgM antibody responses 
were observed in all vaccinated groups during the immuni-
zation period, while those in the two control groups re-
mained unchanged (Fig. 3B).  
Changes  in  IgA-secreting  cells  in  the  lung  and 
intestine
  The number of IgA-secreting cells in the lung and intes-388    Sung Jae Shin et al.
Fig. 4. Representative specimens stained by immunohistochemistry for IgA-secreting cells in the lungs of mice after the final 
immunization. A, group B; B, group D; and C, group E. Arrows indicate positive immunoreactive cells. Counterstaining with 
hematoxylin. ×400.
Table 1. Number of IgA-secreting cells in the lung following oral immunization in each experimental group
Exp. groups
Days
10 20 30 40
Post-
challenge
  A*
B
C
D
E
0.4 ± 0.02
0.2 ± 0.01
 1.6 ± 0.042
2.8 ± 0.46
1.3 ± 0.02
0.1 ± 0.01
0.1 ± 0.06
3.2 ± 0.21
5.2 ± 0.64
6.5 ± 0.02
    0.3 ± 0.031
    0.3 ± 0.013
  4.1 ± 1.03
  9.8 ± 1.48
14.8 ± 1.06
   0.2 ± 0.01
     0.2 ± 0.021
   4.8 ± 0.16
 15.4 ± 1.84
 26.8 ± 11.4
  5.0 ± 1.02
  3.0 ± 0.55
12.5 ± 0.84
22.1 ± 2.23
46.8 ± 5.36
*Group A: PBS control. Group B: S. cerevisiae vector control. Group C: Oral vaccination with S. cerevisiae expressing ApxIA antigen. Group
D: Oral vaccination with S. cerevisiae expressing ApxIIA antigen. Group E: Combined oral vaccination with S. cerevisiae-ApxIA and S. cer-
evisiae-ApxIIA antigen. Values are mean ± SD.
tine was analyzed by counting the number of immunor-
eactive cells and densitometry. Representative specimens 
stained by immunohistochemistry for IgA-secreting cells 
in the lungs after the final immunization are shown in Fig. 
4. The number of IgA-secreting cells significantly in-
creased in the groups immunized with ApxIIA or both anti-
gens after the third immunization, while the number of 
IgA-secreting cells in the group immunized with ApxIA 
increased only after challenge with A. pleuropneumoniae 
(Table 1). However, the relative densities of IgA-secreting 
cells in all vaccinated groups gradually increased after ad-
ditional immunizations in comparison to the control 
groups. The final relative density of the groups immunized 
with ApxIA, ApxIIA, and both antigens were 8.5, 9.5 and 
22.5 times higher than in the PBS-treated control group, re-
spectively (Fig. 5). 
Bacteriological and histopathological examination
  The protective effect of oral immunization with yeast ex-
pressing ApxA antigens was also investigated through his-
topathological scoring and by measuring bacterial clear-
ance at 72 h post challenge. Bacterial clearance was sig-
nificantly enhanced by oral immunization with the anti-
gens in all vaccinated groups (p＜0.05) (Table 2). 
Moreover, the surviving mice showed significantly better 
clearance rates by 36 h post-challenge. The relationship 
between ApxA-specific antibody responses and bacterial 
counts from mouse lungs was further analyzed in the lung 
and sera from the control and vaccinated groups. 
Histopathological lesions, as measured by inflammatory 
indexes, were significantly reduced after vaccination while 
bacterial clearance rates were significantly increased. The 
lowest inflammatory index and the highest bacterial clear-
ance rate were observed in the group immunized with both 
antigens (Table 2).Immune responses with S. cerevisiae expressing rApxIA or rApxIIA    389
Table 2. Bacterial clearance in mice following oral immunization
with yeast expressing rApxA antigens
Immunization 
groups
CFU/mg of 
lung 
(mean ± SD)
Bacterial
clearance rate 
(%)
Inflammatory 
index 
A
B
C
D
E
1554 ± 284
1526 ± 313
  849 ± 300 
  499 ± 213 
  230 ± 143
  0.0 ± 4.3 
  1.8 ± 6.8
  45.3 ± 10.5
67.9 ± 9.8
85.2 ± 8.4
14.5 ± 0.5 
14.0 ± 1.0
  9.7 ± 2.4
  8.6 ± 2.8
  2.2 ± 1.7
*Each group is the same as Table 1.
Fig. 5. Densitometric analysis of IgA immunoreactivity in the 
small intestines of mice orally immunized with S. cerevisiae (□, 
group A; ■, group B; 򰌔򰌔, group C; ▧, group D; ▤, group E). 
Results are expressed as the mean relative density. Asterisks in-
dicate significant differences from the PBS-treated group, *p ＜
0.05 and **p ＜ 0.01.
Fig. 6. Comparison of pro-inflammatory cytokines IL-1β (A), IL-6 (B), and TNF-α (C) from the lung and sera of mice following oral
immunization with S. cerevisiae (□, group A; ■, group B; 򰌔򰌔, group C; ▧, group D; ▤, group E). Bars represent the mean concen-
tration of cytokine proteins. Error bars represent the standard deviation from the mean.390    Sung Jae Shin et al.
Fig. 7. Survival rates of mice immunized with S. cerevisiae after 
being challenged with the minimal lethal dose (MLD) of an A. 
pleuropneumoniae serotype 5 Korean isolate ( , PBS-treated 
control;  , vector control;  , oral immunization with 20  mg
of S. cerevisiae expressing ApxIA antigen;  , oral immuniza-
tion with 20 mg of S. cerevisiae expressing ApxIIA antigen;  ,
oral immunization with 10 mg each of S. cerevisiae expressing 
ApxIA and S. cerevisiae expressing ApxIIA antigen).
Change in proinflammatory cytokines
  The levels of IL-6 and TNF-α significantly increased dur-
ing immunization in the lungs from mice immunized with 
both antigens. However, the levels of IL-1β, IL-6 and 
TNF-α in the lungs of mice from the immunized groups did 
not change significantly after challenge, while the levels of 
these cytokines in the mice in the control groups sig-
nificantly increased after challenge (Fig. 6). The cytokine 
levels in the sera were similarly raised only after challenge, 
with the exception of IL-1β, which did not change sig-
nificantly (Fig. 6A). The production of TNF-α in both the 
sera and lung tissue of mice immunized with both antigens 
was slightly lower than that of the mice in the other groups 
after challenge. 
Survival rates
  All mice were monitored for up to 72 h after challenge 
with the MLD of an A. pleuropneumoniae field isolate. 
Overall, the final survival rates of the vaccinated groups 
were higher than those of the control groups at each time 
point. Notably, all mice in the control groups died at 36 h 
after challenge. The highest survival rate was observed in 
the group immunized with both antigens (Fig. 7). 
  The  correlation  coefficient  (r
2) was calculated by re-
gression analysis in order to determine whether there was 
a correlation between survival rate and antibody response 
or the levels of bacterial colonization. The results showed 
that there was a statistically significant correlation (t test 
for correlation, p < 0.001) between the increase in mucosal 
IgA (r
2 = 0.84), systemic IgG (r
2 = 0.79), and survival rates. 
However, an increase in systemic IgA and IgM did not cor-
relate with the survival rates. Moreover, the number of bac-
teria in the lung correlated negatively with the survival rate 
(r
2 = 0.81). 
Discussion
  Porcine pleuropneumonia caused by A. pleuropneumo-
niae is an important respiratory disease in the swine in-
dustry and has resulted in great economic loss worldwide 
[21]. Although the disease is multifactorial, vaccination 
has been considered to be the most effective strategy for 
protecting swine from A. pleuropneumoniae infection. 
Since most current vaccines are injected and may cause 
many adverse effects [17,18,26], alternative vaccines, in-
cluding oral vaccines, have been sought after [8,18]. In ad-
dition, the induction of immune responses at remote mu-
cosal effector sites through a common mucosal immune 
system has been demonstrated in animal models and has 
been partially confirmed in humans [12,13,22]. When de-
veloping an oral vaccine, it is essential to select an effective 
immunogen, appropriate adjuvant, and proper vaccine reg-
imen [7,20]. We previously explored oral vaccination us-
ing yeast expressing the ApxIIA antigen as an alternative 
and convenient approach against A. pleuropneumoniae in-
fection [34]. However, the protective effect of the oral im-
munization was not sufficient because the bacterium also 
produces other exotoxins. In this study, yeast expressing 
ApxIA were added as a vaccine component because 
ApxIA is also one of the most important factors associated 
with pathogenesis and protective immunity [17]. The effi-
cacy of yeast expressing ApxIA or ApxIIA was evaluated 
using different vaccination regimens in a mouse model be-
fore being applied to the pigs. Mice immunized with pro-
teins extracted from yeast expressing the ApxIA antigen 
produced strong IgG antibody responses and were pro-
tected against challenge, which suggests that the rApxIA 
antigen expressed in S. cerevisiae is highly immunogenic.
  IgA and IgG immune responses increased following oral 
vaccination, and the highest level of response was ob-
served in the group vaccinated with both S. cerevisiae that 
expressed ApxIA or ApxIIA. We also observed a large in-
crease in antigen-specific IgA antibodies and the number 
of IgA-secreting cells in the intestine and lung. Based on 
the findings of other reports [7,8,34], these results strongly 
suggest that mucosal immune responses at remote sites in-
duced by oral immunization are directly related to the ef-
fective production of IgA at the target mucosal site. 
  Only mice immunized with both ApxIA and ApxIIA pro-
duced sufficient humoral immune responses to Apx A tox-
ins and consequently showed the highest survival against 
the challenge. These results compliment those of a pre-
vious report showing that exotoxins were required for the 
full virulence of A. pleuropneumoniae infection [5].  
  TNF-α and IL-6 production in the lung increased after 
vaccination, and IL-1β, TNF-α, and IL-6 production in the 
lung was abrogated only in the vaccinated groups after 
challenge with an A. pleuropneumoniae field isolate. This 
phenomenon might be due to the involvement of IL-6 in Immune responses with S. cerevisiae expressing rApxIA or rApxIIA    391
the production of IgA and the induction of TNF-α by IgA 
[23]. Moreover, the dual capacities of secreted IgA might 
be involved in the mechanism for maintaining balance be-
tween pro-inflammatory and anti-inflammatory activities 
[14,23]. In addition, the prevention of IL-1β, TNF-α and 
IL-6 production was correlated with a decrease in lung le-
sions in the vaccinated groups after challenge.
  The highest bacterial clearance and survival rates were 
observed in the group immunized with both antigens. 
These results might indicate that oral vaccination using 
both antigens could induce more effective protection 
against particularly acute infections by decreasing 
mortality. It was also possible that IgA contributed to the 
protective mechanism by inhibiting the entrance of the 
pathogen into the lung and by modulating the pro-in-
flammatory responses [23,25]. The histopathological le-
sions, such as infiltration of inflammatory cells, were pos-
itively correlated with the groups showing high levels of 
inflammatory cytokine production. These results are in 
good agreement with those of previous studies in which in-
flammatory cell infiltration was mediated by inflammatory 
cytokines [9,10]. Although current thinking is that cell- 
mediated immunity does not play an important role in pro-
tection against A. pleuropneumoniae infection, the role of 
cell-mediated immune responses following oral immuni-
zation needs further investigation. 
  In conclusion, strains of S. cerevisiae that produce ApxA 
antigens could be a promising oral vaccine candidate for 
the prevention of A. pleuropneumoniae acute infection in 
pigs, alone or in combination with other bacterial compo-
nents, and may provide optimal protection both systemi-
cally and at target mucosal sites. 
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